User:Mr. Ibrahem/Margetuximab

Margetuximab, sold under the brand name Margenza, is a medication used to treat metastatic breast cancer that is HER2-positive. It is used in people who have failed prior treatments. It is given by gradual injection into a vein.

Common side effects, when used in combination with chemotherapy, include tiredness, nausea, diarrhea, headache, fever, hair loss, abdominal pain, peripheral neuropathy, muscle pain, shortness of breath, and infusion-related reactions. Use in pregnancy may harm the baby. It is a IgG monoclonal antibody that binds to the human epidermal growth factor receptor 2 (HER2).

Margetuximab was approved for medical use in the United States in 2020. It is not approved in Europe or the United Kingdom as of 2022. In the United States it costs about $9,100 every three weeks for someone who weights 70 kg.